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Background:  Paresthesia  was  the  third-most-common  adverse  event  following  immunization  (AEFI) with
2009  monovalent  AS03-adjuvanted  A(H1N1)pdm09  vaccine  in  Quebec,  Canada  and  was  also  frequently
reported  in  Europe.  This  study  assessed  clinical  features  and  risk  factors  associated  with  this  unexpected
AEFI.
Methods:  Reports  to the  passive  surveillance  system  were summarized.  A  case–control  study  was  con-
ducted  to assess  risk  factors  and  additional  investigations  were  undertaken  among  cases  with  symptoms
persisting  ≥12  months.
Results: There  were  328 reports  of paresthesia  affecting  the  vaccinated  arm  (58%),  but  also  face  (45%),
lower  limbs  (40%)  and  back/thorax  (23%)  with  numbness  but also  muscle  weakness  (61%),  motor  impair-
ment  (61%),  generalized  myalgia  (37%),  visual  (14%)  and/or  speech  effects  (15%).  Reporting  rate was
highest  in  women  of  reproductive  age,  peaking  at 30–39  years-old  (28/100,000  doses  administered)
and exceeding  that  of men  of  the  same  age  (7/100,000  doses)  by  4-fold.  Median  time  to  onset  was 2 h.
Symptoms  subsided  within  one  week  in  37%  but lasted  ≥6  months  in  26%.  No  consistent  or objective  neu-
rological  ﬁndings  were  identiﬁed.  Risk  was  increased  with  allergy  history,  respiratory  illness  the  day of
vaccination,  depressive  symptoms  and family  history  of  pulmonary  disease,  but  decreased  with  physical
activity  the  day  of  vaccination,  and  regular  weekly  alcohol  consumption.
Conclusion:  Paresthesia  following  2009  pandemic  vaccine  receipt  lasted  several  weeks  and  included
other  motor-sensory  disturbances  in  an  important  subset  of patients.  Although  it does  not correspond
with  known  neurological  disease,  and  causality  remains  uncertain,  further  investigation  is warranted  to
understand  the  nature  and  frequency  of  paresthesia  as a possible  AEFI  with  inﬂuenza  vaccines.
© 2015  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).. Introduction
Several pandemic vaccines used in 2009 for the prevention and
ontrol of inﬂuenza during the A(H1N1)pdm09 epidemic have been
ssociated with neurological concerns. An increased risk of the
uillain-Barré syndrome (GBS) has been observed with both adju-
anted and non-adjuvanted pandemic vaccines in some countries
1–4] but not others [5–7]. An increase in narcolepsy has been
∗ Corresponding author at: 2400 avenue d’Estimauville, Quebec G1E 7G9, Canada.
el.: +1 418 666 7000x274; fax: +1 418 666 2776.
E-mail address: gaston.deserres@inspq.qc.ca (G. De Serres).
ttp://dx.doi.org/10.1016/j.vaccine.2015.07.028
264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article 
/).associated with AS03-adjuvanted pandemic vaccine [8–12] but not
with non-adjuvanted vaccines [13,14]. There were also anecdotal
reports of acute disseminated encephalomyelitis [15–20].
In Quebec, the second largest Canadian province (population:
8 million), 4.4 million people were vaccinated during the fall
2009 mass pandemic campaign, of whom 96% received a mono-
valent AS03-adjuvanted pandemic vaccine manufactured locally
(Arepanrix®, GSK Canada). Between 26 October and 31 December,
2009 the Quebec passive Vaccine Adverse Event Reporting Surveil-
lance (VAERS) system received 2229 reports of adverse events
following immunization (AEFI), corresponding to a rate of 50.4 AEFI
per 100,000 doses administered. After allergic-like symptoms (752
reports) [21] and local reactions (402 reports), the third-most-often
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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eported AEFI was paresthesia. This unexpected adverse event was
lso frequently reported in Sweden and France but with no descrip-
ion of its associated clinical features [22–26]. This paper describes
he clinical and epidemiological characteristics of this unexpected
EFI as reported to the Quebec VAERS system and further assessed
n ensuing case–control study and clinical investigations.
. Methods
.1. Passive surveillance
In Quebec, the Public Health Act requires healthcare profession-
ls to report to public health unusual clinical problems temporally
ssociated with vaccination and suspected of being linked to the
accine. To improve the sensitivity of the passive surveillance sys-
em, all physicians received a letter from their Medical Ofﬁcer of
ealth just before the pandemic mass vaccination campaign under-
coring the importance of AEFI reporting in the context of a new
S03-adjuvanted vaccine. The AEFI form includes tick boxes for
dverse events of interest, one of which is anesthesia/paresthesia
nd has a free text zone for additional details. This study includes
eports of paresthesia notiﬁed to VAERS for pandemic vaccines
dministered between 26 October and 31 December, 2009.
.2. Case–control study
The case–control study included cases reported to VAERS aged
8–64 years-old, with onset of anesthesia/paresthesia ≤72 h after
accination, excluding reports of Guillain-Barré Syndrome (GBS).
ontrols were randomly selected from the Quebec pandemic vac-
ination registry of all vaccinated individuals in the province. Since
early three-quarters of the reported cases were female, controls
ere also frequency-matched 3:1 by gender. Identiﬁed controls
ho subsequently reported anesthesia/paresthesia within 72 h of
andemic vaccination were excluded. The chief Medical Ofﬁcer of
ealth legally mandated this investigation that, under the Public
ealth Act, did not require Research Ethics Board approval.
After obtaining verbal consent, a standardized questionnaire
as completed by trained personnel during phone interviews con-
ucted between May  and August 2010, 6–8 months following
accination. The questionnaire systematically assessed clinical pre-
entation among cases. The likelihood of neuropathic pain was
ssessed using the ID Pain questionnaire [27] in each affected limb,
ielding a maximum of four evaluations per case. The highest ID
ain score was kept and categorized as: unlikely (<2), likely (2–3),
r very likely (4–5) to be neuropathic pain [28]. Patients were sent a
tandardized diagram of the human body by mail to show affected
reas. Written consent was requested to access medical records of
ases who had sought health care.
Risk factors evaluated in both cases and controls included health
tatus at vaccination, past personal and family medical history, pre-
cribed medications and over-the-counter products used within
8 h before vaccination, past inﬂuenza vaccination history and
ccurrence of AEFIs with any previous vaccine, smoking, alcohol
onsumption, physical activity and employment.
Numbness may  be a symptom of anxiety, depression, somatiza-
ion or psychosomatic disorders. Accordingly these were assessed
ith four validated psychometric tools, including: (1) the Beck’s
nxiety Inventory short form (BAI-S) which includes 13 questions
29]; (2) the Patient Health Questionnaire 9 (PHQ-9), a 10-item
uestionnaire adapted for the assessment of depression from the
rimary Care Evaluation of Mental Disorders (PRIME-MD) [30]; (3)
he Somatosensory Ampliﬁcation Scale (SSAS), a 10-item question-
aire to evaluate individual sensitivity to normal physical, social,
nd bodily cues and sensations (hunger, ecchymosis, pollutants)Fig. 1. Reported rate of paresthesia per 100,000 doses of AS03-adjuvanted pandemic
vaccine by age and gender.
[31]; and ﬁnally (4) the Forced Choice Symptom Interpreta-
tion Scale to assess individual attributional style, or preferential
interpretation of symptoms within three scales (normalizing, psy-
chologizing, or somatizing) with scores ranging 0–13 [32]. For
example, palpitations can be normalized (interpreted as a sign of
fatigue or excessive caffeine intake), psychologized (sign of ner-
vousness or anxiety) or somatized (sign of serious heart condition).
2.3. Clinical evaluation of persistent cases
Cases with persisting symptoms at the time of the case–control
study were re-contacted in December 2010 (≈12 months post-
vaccination) for participation in further clinical investigation
approved by the institutional research ethics board. After written
informed consent, a neurologist (KL) conducted physical and neu-
rological examinations and 3-Tesla cerebral magnetic resonance
imaging (MRI) scan.
2.4. Statistical analysis
AEFI rates were calculated using denominator data extracted
from the provincial vaccination electronic registry. Proportions
were compared with 2 or Fisher’s exact test and means with the
Kruskal–Wallis test. A Poisson distribution was used to calculate
exact conﬁdence intervals (CIs) and compare rates.
Odds ratios for risk factors and their CIs were estimated by
unconditional logistic regression. The model initially included
factors reaching threshold statistical signiﬁcance (p < 0.15) in uni-
variate analyses. Absence of collinearity was veriﬁed and model
ﬁt was  assessed by the explained deviance and the Hosmer and
Lemeshow test.
3. Results
3.1. Passive surveillance
A total of 328 paresthesia cases (15% of all reported AEFI)
not attributable to GBS were reported through the VAERS sys-
tem. Females accounted for 81% (267) and mean age was 39
years (Table 1). The overall paresthesia rate was 7.5 cases per
100,000 doses administered but varied signiﬁcantly by sex and
age (Fig. 1), lowest in children <10 years-old (0.5/100,000),
increasing through adolescence, and peaking at 30–39 years
(19.5/100,000), then decreasing. After 10 years-of-age, women
were more affected than men  (12.8 vs 3.4/100,000, p < 0.001;
RR = 3.8, 95%CI: 2.8–5.1) although after 60 years-of-age, rates
were similar between men  and women  (2.5/100,000) (Fig. 1).
The reporting rate was  highest in women  30–39 years-old
(28/100,000 doses administered) in whom it exceeded that
of men  of the same age (7/100,000 doses administered) by
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Table 1
Case characteristics by study.
Passive surveillance Case–control Persistent cases
All reported cases Cases with symptom
description
Information from
passive surveillance
Information from
systematic assessment
Information from
systematic assessment
N  = 328 N = 274 N = 181 N = 181 N = 15
n  (%) n (%) n (%) n (%) n (%)
Female 267 (81) 228 (83.2) 155 (86) 155 (86) 13 (87)
Age  (years)
<10 3 (0.9) 2 (0.7) n/a n/a n/a
10–19  27 (8) 22 (8) 3 (2)* 3 (2)* 0 (0)*
20–29 48 (15) 42 (15) 30 (17) 30 (17) 3 (20)
30–39 96 (29) 80 (29) 63 (35) 63 (35) 4 (27)
40–49  87 (27) 75 (27) 53 (30) 53 (30) 6 (40)
50–59  39 (12) 31 (11) 27 (15) 27 (15) 2 (13)
≥  60 28 (9) 22 (8) 5 (3) 5 (3) 0 (0)
Mean  ± SD 39 ± 14 39 ± 14 40 ± 11 40 ± 11 39 ± 10
Median 38 38 39 39 40
Medical history
Allergy (Any) 122 (37) 121 (44) 82 (45) 104 (57) 10 (67)
Taking medication† 93 (28) 91 (33) 55 (30) 114 (63) 8 (53)
Chronic disease** 66 (20) 64 (23) 36 (20) 47 (26) 2 (13)
Health  care workers 69 (21) 68 (25) 53 (29) 41 (23) 4 (27)
Interval between vaccination and symptom onset
<1 h 84 (26) 80 (29) 61 (34) 77 (43) 7 (47)
1–3  33 (10) 30 (11) 26 (14) 28 (15) 3 (20)
4–11  28 (9) 28 (10) 19 (11) 33 (18) 0 (0)
12–23 32 (10) 31 (11) 19 (11) 20 (11) 2 (13)
24–72  50 (15) 45 (16) 23 (13) 23 (13) 3 (20)
>72  17 (5) 15 (6) 0 (0) 0 (0) 0 (0)
Not  speciﬁed 84 (26) 45 (16) 33 (18) 0 (0) 0 (0)
Mean  (median) ± SD 25 (4) ± 72 22 (4) ± 47 10 (2) ± 17 9 (2) ±16 11 (2) ±17
Duration of symptoms
<1 week (<7 days) 131 (40) 129 (47) 86 (48) 67 (37) n/a
1–4  weeks (7–29 days) 63 (19) 62 (23) 35 (19) 35 (19) n/a
1–5  months 8 (2) 7 (3) 8 (4) 24 (13) n/a
≥6  months 0 (0) 0 (0) 0 (0) 4 (2) n/a
Still  ongoing‡ n/a n/a 52 (29) 43 (24) 15 (100)
Impact on daily activities (DA)
Did not interfere 118 (36) 114 (42) 72 (40) n/a n/a
Interfered with DA 80 (24) 73 (27) 49 (27) n/a n/a
Prevented DA 36 (11) 34 (12) 22 (12) n/a n/a
Not  speciﬁed 94 (29) 53 (19) 38 (21) n/a n/a
Medical consultation 137 (42) 128 (47) 81 (45) 106 (59) 13 (87)
Hospitalization 5 (2) 4 (2) 3 (2) 5 (3) 1 (7)
* Only patients ≥18 years of age were eligible.
** Chronic conditions associated with increased risk of inﬂuenza complications.
† Taking medication at time of vaccination.
4
c
u
r
7
w
w
o
(
b
(
A
I
(
A
o‡ Symptoms ongoing at time of the interview 6–8 months post vaccination.
-fold. Most (97%) cases received the AS03-adjuvanted vac-
ine (7.6/100,000; 95%CI: 6.8–8.5), 3 (<1%) received the GSK
nadjuvanted vaccine (2.5/100,000; 95%CI: 0.5–7.2) and 7 (2%)
eceived the CSL unadjuvanted vaccine (19.5/100,000; 95%CI:
.8–40.1).
The median interval between vaccination and symptom onset
as 2 h but 43% reported onset within 1 h and 28% reported onset
ithin 15 min  of vaccination (Table 1, Fig. 2). Paresthesia was most
ften described as numbness (86%) or as prickling/tingling (66%)
Table 2). Pain was reported by 58% and described as a hot or
urning sensation (36%), electric shock-like (23%) or simply as pain
34%). Symptoms consistent with allodynia were reported by 18%.
mong patients reporting pain, the proportion with score on the
D Pain questionnaire indicating neuropathic pain was  “very likely”
score 4–5) was 9% and as “likely” (score 2–3) was 50%.
Paresthesia affected various body parts (Table 2, Fig. 3).
lthough 58% reported symptoms involving the vaccinated arm,
nly 19% had symptoms restricted to this area. The face was affectedin 45%, the lower limbs in 40% and the back/thorax in 23%. Nearly
half (49%) reported hemi-body paresthesia (45% the vaccinated
side, 4% the contralateral side) and in 3%, all limbs were affected.
Affected zone(s) described verbally and/or shown by diagram did
not correspond with a speciﬁc nerve or spinal root territory. Pares-
thesia was  constant in 74% and intermittent in 26%, increasing at
night in 23% and with exercise in 37%.
Motor impairment of upper and lower limbs was reported by
56% and 34% of cases, respectively. Among those with upper limb
numbness, 42% had difﬁculty holding objects and 35% in raising the
affected arm above the head. Among cases with lower limb involve-
ment, difﬁculty was reported by 25% in standing up or walking, 22%
in climbing stairs, and 22% in rising from a chair.
Visual problems were reported by 26 (14%) patients who
described blurring (9), diplopia (6) or black/bright spots (10)
(Table 2). Difﬁculty speaking or enunciating was reported by 27
(15%) cases. Six reported losing consciousness: two  within 15 min
of vaccination and the others at 1.5, 4 and ∼12 h post-vaccination.
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eadache coinciding with paresthesia onset was reported by 38%.
ystemic symptoms were reported by 51% and included general-
zed myalgia in 37%, nausea and vomiting in 27% and fever in 19%.
Medical consultation was reported by 106 (59%) cases and hos-
italization by 5 (3%). The medical charts of 59 cases providing
igned authorization were reviewed. For two cases, medical chart
ade no mention of paresthesia or sensory disturbance. For the 57
ther cases, 42 (74%) consulted at the emergency room and 28 (49%)
onsulted the day of vaccination. Findings from neurological exam
t ﬁrst consultation were described in 32 (56%) charts and were
enerally normal for muscular strength, reﬂexes, and sensitivity.
ne patient had decreased muscular strength involving the lower
Fig. 3. Anatomical areas affected by paresthesia.mptoms (All VAERS, VAERS with symptom description, Case control).
limbs and no strength in the upper right arm. Another patient pre-
sented with decreased sensitivity in all dermatomes of the upper
left arm.
3.2. Case–control study
Among reported cases, 252 (77%) met  inclusion criteria for par-
ticipation in the case–control study. Among the 202 (80%) who
were reached, 16 (6 %) refused to participate and 5 (2%) were
found not to be eligible, leaving 181 participating cases. Among the
1014 controls randomly selected within the vaccination registry,
849 (84%) were reached: 136 (16%) refused to participate, 24 (3%)
reported symptoms ≤7 h following vaccination, and 251 (30%) were
<18 years-old, leaving 438 (52%) participating controls. At the time
of case–control study contact, paresthesia was reported to have
resolved within one week in 37% of cases, but was still present
at 1 and 6 months post-vaccination in 39% and 24%, respectively
(Table 1).
Psychometric assessment showed small but statistically signif-
icant differences in scores of anxiety and depressive symptoms
between cases and controls (Table 3). However, 79% of cases and
89% of controls had normal levels of anxiety (BAI-S score <10), and
70% of cases and 84% of controls had no or minimal depressive
symptoms (PHQ-9 score <5). There was no evidence of somatiza-
tion disorders among cases. Scores on the Symptom Interpretation
Scale were consistent with a somatizing attributional style in only
3% of cases and 2% of controls and scores on the Somato-sensory
ampliﬁcation scale were also similar between cases and controls.
In multivariate analysis, six factors were signiﬁcantly associated
with paresthesia, including increased risk with respiratory illness
on the day of vaccination (OR: 3.44; 95%CI 1.23–9.61), personal
history of allergy (2.37; 95%CI 1.62–3.47) or depressive symptoms
(2.11; 95%CI 1.26–3.56) and family history of pulmonary disease
(1.70; 95% CI 1.05–2.75) (Table 4). Conversely, risk was  decreased
in multivariate analysis with report of physical activity on the day of
vaccination (OR: 0.34; 95% CI 0.17–0.67), or regular weekly alcohol
consumption (0.54; 95% CI 0.37–0.80). However, in combination,
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Table 2
Clinical presentation of cases by study.
Passive surveillance Case–control study Persistent cases
With symptom
description
Information passive
surveillance
Information systematic
assessment
Information systematic
assessment
N  = 274 n (%) N = 181* n (%) N = 181 n (%) N = 15 n (%)
Description of paresthesia
Numbness 233 (85) 143 (79) 156 (86) 15 (100)
Prickling/tingling 56 (20) 34 (19) 119 (66) 12 (80)
Decrease/loss of cutaneous sensation n/a n/a 33 (18) 4 (27)
Pain,  any 89 (33) 57 (32) 104 (58) 12 (80)
Pain 73 (27) 45 (25) 62 (34) 8 (53)
Hot/burning sensation 23 (8) 16 (9) 65 (36) 9 (60)
Electric  shock n/a n/a 41 (23) 6 (40)
Allodynia n/a n/a 33 (18) 4 (27)
Neuropathic ID pain score**
Unlikely (score < 2) n/a n/a 73 (40) 3 (20)
Likely  (score 2–3) n/a n/a 91 (50) 9 (60)
Very  likely (score 4–5) n/a n/a 17 (9) 3 (20)
Areas  affected by paresthesia
Vaccinated arm only 64 (23) 42 (2) 35 (19) 1 (7)
Upper  limb(s) 196 (72) 117 (65) 133 (74) 12 (80)
Lower limb(s) 104 (38) 53 (29) 73 (40) 8 (53)
Face  102 (37) 69 (38) 81 (45) 8 (53)
Back/Torso 26 (10) 14 (8) 42 (23) 6 (40)
Muscle  weakness 48 (18) 24 (13) 110 (61) 11 (73)
Vaccinated arm 34 (12) 19 (11) 77 (43) 6 (40)
Controlateral arm 16 (6) 7 (4) 23 (13) 4 (27)
Ipsilateral leg 25 (9) 10 (6) 28 (16) 2 (13)
Controlateral leg 19 (7) 8 (4) 33 (18) 5 (33)
Upper  limb motor impairment
Difﬁculty holding objects n/a n/a 76 (42) 8 (53)
Vaccinated arm n/a n/a 58 (32) 5 (33)
Controlateral arm n/a n/a 24 (13) 3 (20)
Difﬁculty raising arms above the head n/a n/a 63 (35) 8 (53)
Lower  limb motor impairment
Difﬁculty standing up or walking n/a n/a 45 (25) 7 (47)
Difﬁculty climbing stairs n/a n/a 39 (22) 6 (40)
Difﬁculty getting up from a chair n/a n/a 39 (22) 5 (33)
Other  neurological symptoms
Headache/migraines 30 (11) 19 (11) 69 (38) 10 (67)
Dizziness 29 (11) 21 (12) 80 (44) 10 (67)
Visual problems 7 (3) 4 (2) 26 (14) 6 (40)
Speech  problems n/a n/a 27 (15) 3 (20)
Loss  of consciousness n/a n/a 6 (3) 1 (7)
Systemic symptoms
Fever 2 (1) 2 (1) 35 (19) 4 (27)
Nausea, vomiting 2 (1) 2 (1) 48 (27) 8 (53)
Generalized weakness 26 (10) 13 (7) n/a n/a
Generalized myalgia n/a n/a 66 (37) 9 (60)
Injection site reaction 22 (8) 14 (8) 98 (54) 5 (33)
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r* Description of events only available for 165 cases.
** Based on highest of four possible scores, depending on number of affected area
hese factors explained only a small fraction of paresthesia follow-
ng immunization.
.3. Clinical evaluation of persistent cases
Among the 43 patients still symptomatic 6–8 months post vac-
ination, 24 had persisting symptoms ≈12months post vaccination
nd 15 (62%) agreed to participate in a study of more detailed clin-
cal investigation.
Clinical presentation described 6–8 months post-vaccination
s part of the case–control study was similar between persistent
nd other paresthesia cases (Tables 1 and 2) as were the ﬁndings
n psychometric assessment (not shown). Twelve of 15 cases had
reviously consulted a physician (10 saw a neurologist). Their neu-
ological examination for muscle strength, reﬂexes, and sensitivitywere normal in all but one who had muscular weakness of the lower
limbs and the right arm. Seven patients had a cerebral MRI, four
had an electromyogram, three had a cerebral computed tomogra-
phy scan; all were normal. During the year after symptom onset,
7/15 (47%) patients had missed work because of muscle weakness
and intense fatigue and/or myalgia. One was  absent for one week,
four missed work for 8–10 months and two  for >12 months.
A neurologist (KL) examined persistent cases in January 2011
(13–14 months post vaccination). At that time, 7 patients reported
abnormal sensory perceptions: 3 (20%) had hypoesthesia, one had
hyperesthesia, one had both hypoesthesia and hyperesthesia, one
had thermo-algesia and hypoesthesia and one had all three kinds of
sensory disturbances. Four cases (27%) had muscle weakness affect-
ing lower and/or upper limbs. The rest of the neurological exam
was normal. Cerebral 3-Tesla MRI  performed on 14 patients was
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Table  3
Psychometric assessment among participants in case–control study.
Cases N = 181 n (%) Controls N = 438 n (%) P value
Beck Anxiety Inventory (BAI score, range 0–63)
Normal anxiety (0–9) 143 (79) 390 (89) 0.003
Mild-moderate anxiety(10–18) 19 (11) 32 (7)
Moderate-severe anxiety (19–63) 18 (10) 16 (4)
Mean score ± standard deviation 6 ± 8 4 ± 5 0.009
Depressive symptoms (PRIME-MD score range 0–27)
None (score 0–4) 127 (70) 366 (84) <0.001
Mild  (score 5–9) 30 (17) 52 (12)
Moderate (score 10–14) 12 (7) 16 (4)
Moderately severe (score 15–19) 7 (4) 4 (1)
Severe  (score 20–27) 3 (2) 0
Mean score ± standard deviation 4 ± 5 2 ± 3 <0.001
Somatosensory Ampliﬁcation Scale (SSAS, range 0–50)
Internal stimulus ampliﬁcation (score 0–30)a
Mean ± SD
13 ± 5 13 ± 4 0.63
External stimulus ampliﬁcation (score 0–20)b
Mean ± SD
9 ± 3 9 ± 3 0.57
Overall  Mean ± SD 22 ± 7 22 ± 6 0.54
Forced Choice Symptom Interpretation Scale
Psychologizing 13 (7) 25 (6) 0.46
Normalizing 132 (73) 296 (68) 0.12
Somatising 6 (3) 10 (2) 0.42
No  predominant score 26 (14) 105 (24) 0.009
Values displayed are n/N (%) unless otherwise speciﬁed as mean + - standard deviation.
a
n
u
4
t
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T
R. Items related to sensations of the body.
b . Items referring to environmental variables.
ormal in 10 patients whereas 4 had minor anomalies considered
nrelated to the symptoms.
. DiscussionFollowing mass AS03-adjuvanted pandemic inﬂuenza vaccina-
ion in the fall of 2009, paresthesia was the third-most-common
EFI reported to the Quebec VAERS system. It mostly affected
able 4
isk factors associated with paresthesia after 2009 A(H1N1)pdm09 vaccine receipt and o
Cases N = 181 n (%) Controls N = 43
Personal medical history
Allergy 104 (57.5) 157 (35.8) 
Depression 33 (18.2) 46 (10.5) 
Familial medical history
Pulmonary disease 47 (26.0) 71 (16.2) 
Health status and activities at the time of vaccination
Ill the day of vaccination 13 (7.2) 7 (1.6) 
Physical activity the day of vaccination 12 (6.6) 83 (18.9) 
Working the day of vaccination 104 (57.5) 207 (47.3) 
Regular weekly alcohol consumption 87 (48.1) 279 (63.7) 
Medication within 48 h preceding vaccination
Anti-allergic 7 (3.9) 5 (1.1) 
For  asthma 9 (5.0) 8 (1.8) 
Antibiotics 4 (2.2) 1 (0.2) 
Antidepressants 29 (16.0) 43 (9.8) 
Vitamins 46 (25.4) 155 (35.4) 
Psychometric assessment
Beck Anxiety Inventory score
Normal (<10) 143 (79.0) 390 (89.0) 
All  others (10–29) 38 (21.0) 48 (11.0) 
Depressive symptoms (PRIME MD)
Normal 127 (71.0) 366 (83.6) 
All  others 52 (28.9) 72 (16.4) women of reproductive age, occurred shortly after vaccination and
included not only numbness but also pain (of which 59% were likely
or very likely neuropathic), muscular weakness and motor impair-
ment in more than half, with a smaller proportion also reporting
visual or speech problems. Although symptoms subsided within
one week in nearly 40% of cases, in the remainder paresthesia per-
sisted several weeks, lasting ≥6 months in about one-quarter of
cases contacted in follow-up. Patients seen by physicians had no
dds ratio (OR) in univariate and multivariate analysis (adjusted for age and sex).
8 n (%) p-Value Univariate analysis OR
(95% CI)
Multivariate analysis
OR  (95% CI)
<0.001 2.42 (1.70–3.44) 2.37 (1.62–3.47)
0.01 1.90 (1.17–3.09)
0.007 1.81 (1.16–2.81) 1.70 (1.05–2.75)
<0.001 4.76 (1.87–12.15) 3.44 (1.23–9.61)
<0.001 0.30 (0.16–0.57) 0.34 (0.17–0.67)
0.02 1.51 (1.06–2.13)
<0.001 0.53 (0.37–0.75) 0.54 (0.37–0.80)
0.05 3.48 (1.09–11.12)
0.05 2.81 (1.07–7.41)
0.03 9.88 (1.10–88.97)
0.04 1.75 (1.06–2.91)
0.02 0.62 (0.42–0.92)
<0.001 Ref
2.16 (1.35–3.44)
<0.001 Ref
2.08 (1.38–3.13) 2.11 (1.26–3.56)
4 ccine 3
o
g
r
c
A
f
w
o
s
w
m
s
i
r
u
d
d
p
s
s
c
r
h
o
t
i
y
p
a
o
(
t
r
(
m
a
p
c
t
t
g
a
w
r
p
ﬁ
[
v
P
s
m
2
r
w
t
o
s
t
s
p
b
v
i470 G. De Serres et al. / Va
bjective neurological signs of disease and complementary investi-
ations were usually negative. Despite an extensive list of potential
isk factors, few were signiﬁcantly associated with paresthesia and
ould otherwise explain little of this unexpected but intriguing
EFI.
Paresthesia can be caused by a variety of neurological diseases
or which signs and abnormalities in the ensuing investigation
ill ultimately lead to diagnosis. Idiopathic paresthesia, without
bjective signs of neurological disease, is a frequent reason for con-
ultation in neurology but is less well understood. Some patients
ith paresthesia may  suffer from somatoform disorders [33] but
ost cannot be explained this way. In our study, the array of
ymptoms reported was fairly consistent and sometimes quite
ncapacitating. Despite failure to correspond with a known neu-
ological disease and without objective signs, these reports are
nlikely to have been imagined or due to psychosomatic disor-
ers. A small but statistically signiﬁcant difference in anxiety and
epression was observed in case–control evaluation. However, our
sychometric investigations applying multiple standardized tools
trikingly showed no abnormal level of anxiety, no depressive
ymptoms and no somatizing personalities in the vast majority of
ases. Some paresthesia cases had higher level of anxiety or expe-
ienced depressive symptoms but most reported these symptoms
ad started months after vaccination as a result of the persistence
f paresthesia, the perception of being dismissed by physicians and
he absence of any effective treatment. There was little difference
n comorbidity between cases and controls. In multivariate anal-
sis only respiratory illness on the day of vaccination (OR: 3.44),
ersonal history of allergy (2.37) or depressive symptoms (2.11)
nd family history of pulmonary disease (1.7) increased the risk
f paresthesia whereas physical activity on the day of vaccination
OR: 0.34), or regular weekly alcohol consumption (0.54) decreased
his risk.
Paresthesia after pandemic inﬂuenza vaccination has been
eported not only in Canada but also in Europe, where Pandemrix
the AS03-adjuvanted pandemic vaccine also produced by GSK but
anufactured in Dresden Germany) was largely used. In Sweden,
mong the 769 neurological AEFI reported by health professionals,
aresthesia was second only to dizziness [26]. France reported 583
ases of paresthesias after Pandemrix (14/100,000 doses, or ∼twice
hat reported here) [34]. The European Medicines Agency reported
hat neurological disorders were the second-most-common cate-
ory of AEFIs reported for Pandemrix after general disorder and
dministration site reactions without providing the proportion that
ere paresthesias [35]. While neurological concerns have been
eported to VAERS in the United States where no AS03-adjuvanted
andemic vaccine was used, data were not detailed or stratiﬁed suf-
ciently into subcategories to which paresthesias could be related
36].
While this study cannot deﬁnitively conﬁrm that the pandemic
accine caused paresthesia, several results support this hypothesis.
rior to the pandemic vaccination campaign, the Quebec VAERS
ystem had received just 32 reports of paresthesia among >10
illion doses of seasonal inﬂuenza vaccine administered between
003 and 2009 (0.3/100,000 vaccinated individuals). The rate of
eport to the same system was thus 25-fold higher in association
ith the 2009 AS03-adjuvanted vaccine (7.5/100,000). In 2009,
he distribution of interval between vaccination and symptom
nset was highly skewed to the left: 28% of cases with paresthe-
ia had onset within 15 min  and 43% within 1 h of vaccination. This
ype of epidemic curve is consistent with point-source exposure,
uggesting a causal role for the pandemic vaccine. With tem-
oral coincidence, one would expect the onset of symptoms to
e distributed more equally over the hours and days following
accination. However the epidemiological curve may be skewed
f paresthesias with early onset in relation to vaccination were3 (2015) 4464–4471
better reported than those with later onset. Finally, the age and
sex distribution observed for cases of paresthesia bears a striking
resemblance to that observed with allergic-like reactions associ-
ated with the pandemic vaccine in the same population [21]. The
mechanism explaining this AEFI is unknown. The various anatom-
ical areas affected by paresthesia, the motor impairment of the
upper and lower limbs and visual and speech problems, often
accompanied by generalized fatigue and weakness are sugges-
tive of a systemic phenomenon. With its early onset, this AEFI
may result from the activation of some component of the innate
immune system. Correlation with adolescence and reproductive
age in women suggests some hormonal inﬂuence may  also be at
play.
This study has limitations. The participation rate including 74%
of eligible cases and 76% of controls that were reached is reassur-
ing with respect to representativeness. Our passive VAERS system
has imperfect/low sensitivity and despite reminder underscoring
its particular importance in relation to the pandemic vaccination
campaign, likely missed many cases. Cases with more severe symp-
toms were likely more often reported than milder events and may
not be representative of all cases. There are no estimates of the sen-
sitivity of VAERS in Quebec or in Canada but in the United States,
sensitivity varied considerably from 75% for serious adverse events
(like vaccine-induced polio) to less than 1% for rash [37]. In the
context of the 2009 pandemic vaccination in Canada during which
there was substantial media attention regarding uncertain safety
of the novel adjuvanted vaccine, the sensitivity of VAERS in Quebec
was probably greater than usual. The overall rate of AEFI reporting
was 2.6 times higher than for seasonal non-adjuvanted inﬂuenza
vaccine during the previous six years (50 vs 19 per 100,000 doses
administered) likely reﬂecting both better reporting and a more
reactogenic vaccine [21]. For Guillain Barre Syndrome, 61% of the
101 possible cases were passively reported during the pandemic
period [4] but that proportion is likely to be lower for milder and
unexpected AEFIs like paresthesia. The case–control study con-
ducted 7–9 months after vaccination may have resulted in some
recall bias. The absence of a complete neurological examination
and other diagnostic tests (e.g. electrodiagnostic procedures) at the
time of occurrence for most cases limits our capacity to describe the
objective signs of the syndrome. Ultimately, there are uncertain-
ties regarding causality between paresthesia and vaccine receipt.
Despite caveats, our systematic assessment provides important
documentation and description that will be critical to consider not
only for the AS03-adjuvanted inﬂuenza vaccine but also for unad-
juvanted products (whose rates of paresthesia were no lower) and
for seasonal vaccines.
In conclusion, use of the AS03-adjuvanted monovalent inﬂuenza
A(H1N1)pdm09 vaccine was  associated with a non-trivial and
often prolonged syndrome that included not only paresthesia but
also other motor-sensory disturbances that do not readily corre-
spond with a known neurological disease. The limited reporting of
paresthesia following seasonal inﬂuenza vaccine in the six seasons
preceding the 2009 pandemic vaccination suggests that this AEFI
may also occur with other (non-adjuvanted) inﬂuenza vaccines but
at a much lower rate. The etiologies of idiosyncratic paresthesias
seen by neurologists outside the context of vaccination are also
unknown. These may  share a common pathophysiologic pathway
for which current knowledge and understanding remain lacking.
Paresthesia is not currently a recognized adverse event of inﬂuenza
vaccination. While not fully conclusive, these pronounced safety
signals from Canada and Europe that emerged during the mass
2009 pandemic vaccination campaign should not be dismissed as
artifacts of surveillance or psychological considerations. Ongoing
vigilance and further investigation are warranted to understand
the nature and frequency of paresthesia as a possible AEFI with
inﬂuenza vaccines.
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